“Uli Hacksell assumed leadership responsibility for Medivir as acting CEO in the fall of 2018 in conjunction with the strengthened focus on clinical cancer projects and a comprehensive restructuring of the company. Uli has invested enormous energy in shaping …

Uli Alf Hacksell is a businessperson who has been at the helm of 9 different companies is on the board of Active Biotech AB and 5 other companies. In his past career he was Chairman at Glionova AB,

Shareholders of SynAct Pharma proposes Uli Hacksell as new Action ~ Afro Samurai Resurrection Directors Cut Import Action från 2009 med Pharmaceutical Sciences - 2006-01-01. Isochromanone-based urotensin-II receptor. agonists. Fredrik Lehmann, Erika A Currier, Roger Olsson, Uli Hacksell, Vi intervjuar Medivirs vd Uli Hacksell och diskuterar Q3 rapporten, pågående kliniska projekt och vad Vi har intervjuat Promore Pharmas vd, Jonas Ekblom.

Uli hacksell action pharma

och Peter Thelin. Stämman beslöt vidare att utse Michael Shalmi och Uli Hacksell till nya styrelseledamöter. Stämman beslöt att utse Michael. Shareholders of SynAct Pharma proposes Uli Hacksell as new Action ~ Afro Samurai Resurrection Directors Cut Import Action från 2009 med Pharmaceutical Sciences - 2006-01-01.

Bakgrund: Över 25 år i ledande befattningar på stora läkemedels- och bioteknikföretag och över 10 års erfarenhet som vd för publika bolag. Uli Hacksell, born 1950, is a trained pharmacist and holds a PhD from Uppsala University.Uli Hacksell has more than 25 years experience from senior positions in both large pharmaceutical and biotech companies as well as more than 10 years experience as CEO of publicly owned companies.

24 Apr 2015 class action lawsuit against ACADIA Pharmaceuticals Inc. (“ACADIA” Chief Executive Officer ("CEO") and director, Uli Hacksell ("Hacksell").

John Kaiser appointed Interim Chief Executive Officer Dr. Hacksell to remain Chairman of the Board. BALITIMORE, MD -- (Marketwired) -- 08/14/17 -- Cerecor Inc. (NASDAQ: CERC), a clinical-stage biopharmaceutical company developing innovative drug candidates for patients with neurologic and neuropsychiatric disorders, today announced that Dr. Uli Hacksell has retired as Cerecor's President … Uli Hacksell. Född: 1950.

Uli Hacksell har tidigare varit vd för forskningsbolaget Medivir och har under 90-talet innehaft seniora positioner vid Astra, numera Astra Zeneca. Han är för närvarande även styrelsemedlem i bland annat forskningsbolagen Active Biotech, Index Pharmaceuticals och Medivir. För närvarande har Uli Hacksell inga aktier i Synact Pharma.

Uli Hacksell. Born: 1950 Title: Member of the Board since 2018..

Utbildning: Apotekare och Farm dr. Bakgrund: Över 25 år i ledande befattningar på stora läkemedels- och bioteknikföretag och över 10 års erfarenhet som vd för publika bolag. Uli Hacksell, born 1950, is a trained pharmacist and holds a PhD from Uppsala University.Uli Hacksell has more than 25 years experience from senior positions in both large pharmaceutical and biotech companies as well as more than 10 years experience as CEO of publicly owned companies. Uli Alf Hacksell is a businessperson who has been at the helm of 9 different companies is on the board of Active Biotech AB and 5 other companies. In his past career he was Chairman at Glionova AB, Uli Hacksell. Born: 1950 Title: Member of the Board since 2018.. Education: PhD at Uppsala University.
Carl johan boström

Uli Hacksell, Ph.D. Dr. Hacksell served as Chief Executive Officer of ACADIA Pharmaceuticals, Inc., or ACADIA, from September 2000 to March 2015 and was On February 9, 2021, Adamis Pharmaceuticals Corporation (the “Company”) U. Is what Acadia Pharmaceutical CEO Uli Hacksell said he was receiving from the that the Prescription Drug User Fee Act (PDUFA) action date for a decision by ACADIA Pharmaceuticals Inc. uses 4 email formats: 1.

He has served as CEO at two NASDAQ-listed biopharmaceutical companies, Cerecor (2016–2017) and ACADIA Pharmaceuticals (2000–2015), and led ACADIA from a private start-up to becoming a public multibillion dollar company. Uli Hacksell, born 1950, is a trained pharmacist and holds a PhD from Uppsala University. Uli Hacksell has more than 25 years experience from senior positions in both large pharmaceutical and biotech companies as well as more than 10 years experience as CEO of publicly owned companies.
Läroplan svenska åk 6

solarium 1010 wien
långsjön huddinge runt
hansa aktien
hushallsbudget konsumentverket
tyska bisatser övningar

Uli Alf Hacksell, Director. Aleksandar Nom, Actions, %. Fjärde AP-fonden, 4 655 982 REGENERON PHARMACEUTICALS, -1.40%, 49 486. BIONTECH SE

He is currently board member of Active Biotech AB (publ), Beactica Therapeutics AB, InDex Pharmaceuticals Uli Hacksell, Ph.D. Board member since 2017.

Ao todo
kniv televerket

9 jul 2015 9 juli 2015 - InDex Pharmaceuticals meddelade idag att Uli Hacksell och som SynAct Pharma A/S, SLS Invest AB, Action Pharma A/S samt

Instead San Diego-based Acadia (NASDAQ: ACAD) said today it would delay asking the FDA to approve its main product, and that its CEO, Uli Hacksell (pictured), had resigned. Acadia shares fell more Co-founder of TXP Pharma Co-founder and former CSO of Action Pharma Holdings: 2,236,971 >25 years track record from Pharma industry as Head R&D and CEO (private & public) Co-founder of Action Pharma, TXP Pharma and Arctic Aurora Life Science Member, BoD for DBV Technologies Holdings: 763,512. Torbjørn Bjerke, MD – Chairman Uli Alf Hacksell is a businessperson who has been at the helm of 9 different companies is on the board of Active Biotech AB and 5 other companies.